HC Wainwright & Co. maintains Agios Pharmaceuticals at Buy, raises price target to $62 from $55

HC Wainwright & Co. kept its Buy rating on Agios Pharmaceuticals and raised its price target to $62 from $55, citing a 12.7% increase. This implies an upside of 119.3% from the Nov 5 close of $28.27.

Original reporting
Published Nov 6, 2026, 11:41 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 11:49 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
HC Wainwright & Co. maintains Agios Pharmaceuticals at Buy, raises price target to $62 from $55 — source image
Decision brief

The 30-second read

$AGIOBullishMed
01

Why it matters

The price target increase signals confidence in Agios' pipeline, potentially prompting short-term buying.

02

Market read

Analyst price target upgrades are modest catalysts that can generate short-term price moves in small-cap biotech stocks.

03

What to watch

Potential dilution from future financing or regulatory setbacks.

Relevance 6/10Novelty 6/10Timing: today

Background

HC Wainwright is a mid-size research firm; its upgrades can move small-cap biotech stocks.

Company-level read

Ticker impact

$AGIOBullishHigh confidence
Context

HC Wainwright raised Agios Pharmaceuticals' price target to $62 from $55, indicating a bullish outlook.

Expected impact

likely upward pressure as investors price in the higher target

Evidence & confidence

The new target represents a 12.7% increase and implies a 119% upside from the current price, which can attract buying interest.

Market effects

May lift sentiment in the biotech sector as analysts raise targets.

Limited to US biotech equities.

Low, confined to Agios and peers.

Counterpoint

The target raise could be premature if upcoming trial data disappoints.

Key entities

  • HC Wainwright & Co.

    Provided the upgraded rating and price target.

  • Agios Pharmaceuticals

    Subject of the analyst upgrade.

Related articles

$AGIOMed

Agios Earnings Call: AQVESME Growth Meets FDA Uncertainty

Agios Pharmaceuticals (AGIO) reported Q3 revenue of $55.4M, up from $12.9M a year earlier, driven by strong AQVESME adoption. The company saw 177 new prescriptions, with 75% patient persistence. International revenue rose 74% to $6.6M. Agios prepares for a potential sickle cell launch, but faces FDA review extension and higher expenses. Q3 net loss narrowed to $65M from $103M YoY.

$AGIOMed

Agios Pharmaceuticals Inc (AGIO) (Q3 2026) Earnings Call Highlights: Revenue Surges 4x

Agios Pharmaceuticals (AGIO) reported Q3 2026 revenue surged 4x, but faced a 3-month FDA review delay for mitapivat in sickle cell disease, increasing uncertainty. Net loss narrowed to $65M from $103.4M YoY. Selling expenses rose to $56.5M, and no 2027 guidance was provided. Thalassemia launch growth may moderate, with 177 prescriptions as a new run rate. Pipeline programs remain early-stage.

$AGIOMed

Agios Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary

Agios Pharmaceuticals reported Q3 2026 revenue of $55.4M, driven by mitapivat in thalassemia. The company plans to cut R&D headcount by 35% to focus on rare hematology and aims for non-GAAP profitability in 2028. Mitapivat's sickle cell disease approval was delayed to February 2027 due to FDA review. The company is also advancing AG-236 for polycythemia vera and cevidoplenib for immune thrombocytopenia.

$AGIOMed

Agios (AGIO) Q3 2026 Earnings Call Transcript

Agios (AGIO) reported Q3 2026 earnings, highlighting $55.4M in mitapivat revenue, a 3-month FDA review extension for sickle cell disease, and $907M in cash. The company plans to reduce R&D headcount by 35% and aims for non-GAAP profitability in 2028. Mitapivat saw a 4x revenue increase YoY, with strong U.S. and international demand.

$AGIOHigh

Truist cuts Agios Pharma stock price target on SCD concerns

Truist Securities reduced its price target for Agios Pharmaceuticals (NASDAQ: AGIO) to $35 from $37, citing concerns about sickle cell disease. The stock is currently trading at $28.38, down 15.7% over the past week. Agios reported Q3 2026 earnings that missed expectations, but revenue exceeded estimates. The company announced a 35% reduction in R&D headcount, aiming for non-GAAP profitability in 2028.

$AGIOHigh

Agios Q3 Mitapivat Revenue Surges More Than Fourfold; Sickle Cell FDA Decision Set For February 2027

Agios Pharmaceuticals (AGIO) reported Q3 2026 revenue of $55.4M for mitapivat products, up over fourfold YoY. U.S. revenue rose to $48.7M, while ex-U.S. revenue increased to $6.6M. Net loss narrowed to $65.0M. The FDA extended the PDUFA goal date for mitapivat in sickle cell disease to February 2027. Agios plans to reduce R&D workforce by over 35% by year-end 2026.